Fig. 2.
Cumulative incidence of cardiac adverse events. Cumulative incidence of cardiac adverse events associated with bortezomib (solid line) and carfilzomib (dashed line) in relation to duration of therapy shown in days
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.